Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.
Asher Chanan‐Khan, Zhinuan Yu, Donna Weber, Christine Chen, Rubén Niesvizky, Andrew Spencer, Michel Attal, Andrew R. Belch, Miles Prince, Marta Olesnyckyj, Robert Knight, Jerome B. Zeldis, Meletios A Dimopoulos (2006). Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. , 108(11), DOI: https://doi.org/10.1182/blood.v108.11.3554.3554.
